Wells Fargo Initiates Coverage On Cytokinetics with Overweight Rating, Announces Price Target of $95

Benzinga Newsdesk www.benzinga.com Neutral 60.7%

Neg 0% Neu 60.7% Pos 0%

Wells Fargo analyst Yanan Zhu initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Overweight rating and announces Price Target of $95.